Effect of adalimumab on extraintestinal manifestations among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA

Effect of adalimumab on extraintestinal manifestations among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA

Extraintestinal manifestations (EIMs) are common in patients with ulcerative colitis (UC) and can have a significant impact on patient morbidity and quality of life. We assessed the effect of adalimumab (ADA) therapy on the resolution of EIMs among patients with moderate to severe UC in clinical pra...

Descripció completa

Dades bibliogràfiques
Autors principals:	Travis, S, Feagan, B, Peyrin-Biroulet, L, Panaccione, R, Danese, S, Lazar, A, Robinson, A, Thakkar, R, Pappalardo, B, Petersson, J, Bereswill, M, Chen, N, Skup, M
Format:	Journal article
Publicat:	Oxford University Press 2017

Ítems similars

Effect of adalimumab dose escalation on clinical, health-related quality of life, treatment satisfaction and work productivity outcomes among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA
per: Travis, S, et al.
Publicat: (2017)

Effect of adalimumab on clinical outcomes and health-related quality of life among patients with ulcerative colitis in a clinical practice setting: Results from inspirADA
per: Travis, S, et al.
Publicat: (2017)

Effect of adalimumab on clinical outcomes and health-related quality of life among patients with ulcerative colitis in a clinical practice setting: Results From InspirADA.
per: Travis, S, et al.
Publicat: (2017)

The Crohn's disease–ulcerative colitis clinical appraisal update: emerging trends in clinical practice
per: Sandborn, W, et al.
Publicat: (2016)

Does it all ADA up? Adalimumab for ulcerative colitis.
per: Travis, S
Publicat: (2011)

Should extraintestinal manifestations (EIMs) be part of disease activity assessment in ulcerative colitis?
per: Walsh, A, et al.
Publicat: (2018)

Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy
per: Napolitano M, et al.
Publicat: (2022-06-01)

Immune Thrombocytopenic Purpura as an Extraintestinal Manifestation in a Patient with Ulcerative Colitis
per: Renata de Medeiros Dutra, et al.
Publicat: (2022-03-01)

Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis
per: David T. Rubin, et al.
Publicat: (2021-05-01)

Raising the bar in ulcerative colitis management
per: Fabrizio Fanizzi, et al.
Publicat: (2024-11-01)

Pulmonary Extraintestinal Manifestation of Crohn’s Disease Treated Successfully with Adalimumab
per: Dongyeol Shin, et al.
Publicat: (2018-09-01)

Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience
per: Ferdinando D’Amico, et al.
Publicat: (2019-05-01)

A Case of Syrian Child with Cerebral Infarction as an Extraintestinal Manifestation of Ulcerative Colitis
per: Riham Salloum, et al.
Publicat: (2019-01-01)

Increased Demand for Therapeutic Drugs in Pediatric Ulcerative Colitis Patients With Extraintestinal Manifestations
per: Yiyoung Kwon, et al.
Publicat: (2022-05-01)

Meta‐analysis of the association of extraintestinal manifestations with the development of pouchitis in patients with ulcerative colitis
per: K. Hata, et al.
Publicat: (2019-08-01)

Role of Probiotics in the Management of Patients with Ulcerative Colitis and Pouchitis
per: Francesca Bernardi, et al.
Publicat: (2024-12-01)

Multiple extraintestinal manifestations in a patient with acute severe ulcerative colitis: a case report
per: Eun Young Park, et al.
Publicat: (2022-12-01)

Factors Associated with the Presence of Extraintestinal Manifestations in Patients with Ulcerative Colitis in a Latin American Country
per: Jesús K. Yamamoto-Furusho, et al.
Publicat: (2020-10-01)

Infliximab versus Adalimumab, Which One Is Better for Ulcerative Colitis?
per: Eun Soo Kim
Publicat: (2021-03-01)

Febrile neutropenia associated with adalimumab in a patient with ulcerative colitis
per: Ma’In Atallah Mohammad Abumuhfouz, et al.
Publicat: (2024-04-01)

Albumin change predicts failure in ulcerative colitis treated with adalimumab
per: Natsuki Ishida, et al.
Publicat: (2024-01-01)

Adalimumab-associated bullous pemphigoid in a patient with ulcerative colitis
per: Laurel L. Wessman, BS, et al.
Publicat: (2017-07-01)

Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
per: Assasi Nazila, et al.
Publicat: (2009-12-01)

Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab
per: Armuzzi A, et al.
Publicat: (2013-04-01)

Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab
per: Freeman HJ
Publicat: (2013-11-01)

Real-World Maintenance Phase Persistence on Ustekinumab and Adalimumab in Ulcerative Colitis
per: Zhdanava M, et al.
Publicat: (2024-04-01)

Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus
per: Vuitton, L, et al.
Publicat: (2017)

Understanding the Role of Adalimumab in the Treatment of Moderately to Severely Active Ulcerative Colitis
Publicat: (2016-03-01)

Bullous Pemphigoid Associated with Adalimumab Therapy in a Patient with Ulcerative Colitis
per: Sebastian Hoffmann, et al.
Publicat: (2018-05-01)

ADALIMUMAB FOR ULCERATIVE COLITIS: RESULTS OF A BRAZILIAN MULTICENTER OBSERVATIONAL STUDY
per: Patrícia ZACHARIAS, et al.
Publicat: (2017-10-01)

Leukocytoclastic Vasculitis as a Rare Dermatologic Extraintestinal Manifestation of Ulcerative Colitis in an Elderly Patient with Positive PR3-ANCA
per: Jacky Ng, et al.
Publicat: (2021-01-01)

Exploring genetic associations of Crohn’s disease and ulcerative colitis with extraintestinal cancers in European and East Asian populations
per: Chengdong Yu, et al.
Publicat: (2024-02-01)

Steroid-refractory extensive enteritis complicated by ulcerative colitis successfully treated with adalimumab
per: Shinji Okabayashi, et al.
Publicat: (2017-10-01)

Comparison of long-term outcomes of infliximab and adalimumab therapy in biologic-naive patients with ulcerative colitis
per: Muhammed B. Durak, et al.
Publicat: (2025-01-01)

International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult Patients
per: Bénédicte Caron, et al.
Publicat: (2023-01-01)

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS).
per: Travis, S, et al.
Publicat: (2012)

Henoch-Schönlein Purpura with Adalimumab Therapy for Ulcerative Colitis: A Case Report and Review of the Literature
per: Joseph J. LaConti, et al.
Publicat: (2016-01-01)

Effectiveness of adalimumab in severe ulcerative colitis: A systematic review and a meta‐analysis
per: Saleh Azadbakht, et al.
Publicat: (2024-07-01)

Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis
per: Candace L. Beilman, et al.
Publicat: (2016-01-01)

Adalimumab biosimilars in the therapy of Crohn´s disease and ulcerative colitis: Prospective multicentric clinical monitoring.
per: Martin Wasserbauer, et al.
Publicat: (2022-01-01)